A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer
Journal of Interventional Medicine, 2023 Liver malignancy, including primary liver cancer and metastatic liver cancer, has become one of the most common causes of cancer-related death worldwide due to the high malignant degree and limited systematic treatment strategy.
Yasaman Anbari +9 more
semanticscholar +1 more source
The physics of radioembolization [PDF]
EJNMMI Physics, 2018 Radioembolization is an established treatment for chemoresistant and unresectable liver cancers. Currently, treatment planning is often based on semi-empirical methods, which yield acceptable toxicity profiles and have enabled the large-scale application in a palliative setting.
Remco Bastiaannet +5 more
openaire +4 more sources
PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. [PDF]
, 2016 PurposeThe purpose of our study is to determine if there is a relationship between dose deposition measured by PET/MRI and individual lesion response to yttrium-90 ((90)Y) microsphere radioembolization.Materials and methods26 patients undergoing lobar ...
Fowler, Kathryn J +7 more
core +2 more sources
Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma, 2023 Background The purpose of this study was to assess the safety and efficacy of Yttrium-90 radioembolization using in unresectable hepatocellular carcinoma.
Chun-Yen Yu +10 more
semanticscholar +1 more source
Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity [PDF]
, 2017 Aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of unresectable intrahepatic cholangiocarcinoma (UICC). Materials & methods: Institutional Review Board-approved, retrospective search was performed.
Akinwande, Olaguoke +6 more
core +2 more sources
Holmium-166 Radioembolization: Current Status and Future Prospective
Cardiovascular and Interventional Radiology, 2022 Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (166Ho) caught the experts’ attention due to its imaging possibilities.
M. Stella +4 more
semanticscholar +1 more source
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Journal of Clinical Oncology, 2021 PURPOSE To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM). METHODS In this international, multicenter, open-label phase III trial, patients
M. Mulcahy +23 more
semanticscholar +1 more source
Radioembolization in the setting of liver transplantation. Great expectations or hard times? [PDF]
, 2018 Trans-arterial radio-embolization (TARE) with yttrium-90 represents one of the most efficacious approaches for the treatment of selected patients with advanced hepatocellular cancer (HCC) (1).
Lai, Quirino, Mennini, Gianluca
core +1 more source